New Study: Cost-Effectiveness of Diabetes Medications

A comprehensive systematic review published in Clinical Drug Investigation has analyzed the long-term cost-effectiveness of newer antidiabetic drugs (NADs) for type 2 diabetes management across global healthcare systems. The study, led by researchers Li, Smith, and Marra, examined 142 studies to provide crucial insights into the economic value of modern diabetes treatments, including recently introduced agents like tirzepatide and finerenone.

What This Study Found

The systematic review analyzed cost-effectiveness data from studies published between January 2008 and February 2025, examining newer antidiabetic medications compared to conventional therapies. The researchers found that 81% of incremental cost-effectiveness ratio-based analyses reported that newer antidiabetic drugs were cost-effective when compared to conventional therapies, based on country-specific willingness-to-pay thresholds.

However, the study revealed significant disparities based on economic development levels. Using Thailand as an example of a developing country, the researchers found that NADs were generally not cost-effective, primarily because willingness-to-pay thresholds (USD 4,336-5,310 per quality-adjusted life-year) were substantially lower than those in higher-income settings.

The study suggests that recently introduced agents, including tirzepatide and finerenone, along with early-line use of NADs, were typically cost-effective only at higher willingness-to-pay thresholds (USD 100,000-150,000 per quality-adjusted life-year) or following substantial price reductions. The researchers found that sodium glucose cotransporter-2 inhibitors would require price reductions of 70% or greater, while oral glucagon-like peptide-1 receptor agonists would need reductions of 90% or greater to achieve cost-effectiveness in lower-income settings.

Clinical Significance

The research suggests that newer antidiabetic drugs provide favorable long-term cost-effectiveness primarily due to their cardiovascular and renal protective benefits. This finding is particularly significant given the rising global burden of type 2 diabetes and the increasing pressure on healthcare systems to demonstrate value for money in treatment decisions.

The study's analysis of established diabetes models employing lifetime horizons from a payer perspective provides healthcare decision-makers with comprehensive evidence for formulary and treatment guideline decisions. The researchers found that most evaluations supported the long-term economic value of NADs when considering their broader health benefits beyond glycemic control.

However, the study also highlights methodological challenges in long-term economic modeling. The researchers noted substantial heterogeneity across studies and acknowledged limitations inherent to economic modeling that extend over decades. This suggests that while the overall evidence supports NAD cost-effectiveness, individual treatment decisions should consider multiple factors beyond economic analyses alone.

Current Access and Compliance Context

The systematic review reveals significant global disparities in medication access based on economic factors. The researchers found that willingness-to-pay thresholds vary dramatically between countries, with developing nations facing substantial barriers to accessing newer diabetes treatments due to cost considerations.

The study suggests that current pricing structures may limit equitable access to innovative diabetes treatments in resource-constrained settings. This finding underscores the need for pricing strategies that consider local economic conditions and healthcare system capacities.

The research also indicates that early-line use of newer agents—potentially offering the greatest clinical benefit by preventing complications—may be economically feasible only in higher-income settings without significant price adjustments. This creates a potential paradox where the most cost-effective long-term strategy may be financially inaccessible to many healthcare systems.

What Patients Should Know

Patients with type 2 diabetes should understand that this research suggests newer medications may provide better long-term value through their cardiovascular and kidney protective effects, even though initial costs may be higher than traditional treatments.

The study's findings indicate that the economic benefits of newer diabetes drugs become more apparent over longer time periods, particularly when considering reduced hospitalizations and complications. However, immediate out-of-pocket costs may vary significantly based on insurance coverage and geographic location.

Patients should discuss with their healthcare providers how this economic evidence applies to their individual circumstances, including their specific risk factors for diabetes complications and their insurance coverage for different medication options. The research suggests that early intervention with effective treatments may provide better long-term outcomes and potentially lower overall healthcare costs.

It's important for patients to understand that cost-effectiveness at a healthcare system level may not directly translate to individual affordability, and treatment decisions should always prioritize clinical appropriateness and safety.

If you're managing type 2 diabetes and want to explore your treatment options with a qualified healthcare provider, visit peptideassociation.org/find-a-doctor to connect with specialists in your area who can help develop an appropriate treatment plan based on your individual needs and circumstances.

Medical Disclaimer: This content is for educational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any changes to your diabetes treatment plan. Individual treatment decisions should be based on comprehensive medical evaluation and consideration of personal health factors.

Citation: Li D, Smith A, Marra CA. Global Long-Term Cost Effectiveness of Newer Antidiabetic Drugs for Type 2 Diabetes Mellitus: A Systematic Review. Clin Drug Investig. 2026;41811592. doi:10.1007/s40261-026-01530-6